<DOC>
	<DOCNO>NCT00294437</DOCNO>
	<brief_summary>To determine therapy Zometa® ( zoledronic acid ) 4mg effective prevent occurrence bone metastases prostate cancer patient high risk develop . In addition , pain analgesic score overall safety evaluate throughout study .</brief_summary>
	<brief_title>ZOMETA® ( Zoledronic Acid ) Prevention Bone Metastases</brief_title>
	<detailed_description>This prospective , randomize , stratify open-label ( Zometa + hormonal ablation versus hormonal ablation alone ) multicenter clinical study evaluate efficacy Zometa 4mg give every 3 month adjunct hormonal surgical castration prevention bone metastases locally advanced , high risk prostate cancer patient , hormone-naiv time randomization . primary efficacy variable time occurrence first bone metastasis . Zometa® ( zoledronic acid ) provide 4mg lyophilised powder Supplementation 500mg Calcium +400-500IU Vitamin D p.o . qd Arm A : Zometa® ( zoledronic acid ) 100ml calcium free solution i.v . 15 minute infusion every 3 month Arm B : reference therapy</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Signed informed consent Age &gt; 18 year Histologically confirm diagnosis carcinoma prostate ECOG performance status 0 , 1 , 2 No radiological evident bone metastasis ( negative bone scan verification suspect foci benign lesion additional radiological examination ) T34 AND high prestudy PSA &gt; 20 ng/ml AND Gleason score = 8 ( Gleason grade = 4 ) Patients prior prostatectomy prior local radiotherapy eligible study Patients destine receive medical ( LHRH analogue ) surgical ( orchiectomy ) castration Zometa® treatment start later 6 week surgery Patients fully recover prior intervention applicable Patients serum creatinine determination &gt; 265 µmol/L ( 3.0 mg/dL ) Patients receive prior medical ( LHRH analogue ) castration Current ( previous ) evidence metastatic disease bone History neoplasm within past five year except nonmelanomatous skin cancer . Previous hormonal therapy LHRH agonists form hormonal ablation WBC &lt; 3.0x109 , ANC &lt; 1500/mm3 , Hgb &lt; 8.0 g/dL , platelet &lt; 75 x 109/L Liver function test &gt; 2.5 ULN Prior treatment Zometa® ( zoledronic acid ) bisphosphonates Treatment calcitonin , mithramycin , gallium nitrate within 2 week prior date randomization ( Visit 2 ) Use investigational drug ( drug market indication ) within 30 day prior date randomization ( Visit 2 ) Patients evidence six month prior randomization severe cardiovascular disease ( define uncontrolled congestive heart failure ) , hypertension refractory treatment , symptomatic coronary artery disease uncontrolled treatment History noncompliance medical regimen patient consider potentially unreliable incapable give informed consent judge investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Zometa</keyword>
</DOC>